#23–Tom Dayspring Part IV of V: statins, Zetia, PCSK9 inhibitors, niacin, cholesterol & the brain

ℹ️ EPISODE INFO

Released

January 1, 2020

Duration

2h 0m

Channel

Peter Attia MD

Watch on YouTube

▶ Open ↗

📝 EPISODE DESCRIPTION

Original release date: 10/18/2018 In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter’s most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part IV, Peter and Tom review the history and current use of drugs to prevent cardiovascular disease. They also discuss why some drugs appear to be more effective than others, an in-depth conversation about niacin, cholesterol and brain health, and the futility of using CKs (creatinine kinase) and liver function tests to identify adverse effects in statins, to name a few topics in this episode. We discuss: -Bile acid sequestrants and statins [2:00]; -Ezetimibe (Zetia) [15:00]; -PCSK9 inhibitors [27:30]; -Fibrates [41:00]; -Fish oil, DHA, and EPA [1:01:00]; -Niacin [1:05:15]; -PCSK9 inhibitors [1:23:45]; -Cholesterol, statins, and the brain [1:30:00]; -Elevated creatine kinase (CK) and liver function tests (LFTs) on statins [1:50:30]; and -More. Show notes page: https://peterattiamd.com/tomdayspring4/ About: The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 10 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more. Peter is the founder of Attia Medical, PC, a medical practice with offices in San Diego and New York City, focusing on the applied science of longevity. The practice applies nutritional biochemistry, exercise physiology, sleep physiology, techniques to increase distress tolerance, lipidology, pharmacology, and four-system endocrinology to increase lifespan (delaying the onset of chronic disease), while simultaneously improving healthspan (quality of life). Learn more: https://peterattiamd.com/ Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on: Facebook: http://bit.ly/PeterAttiaMDFB Twitter: http://bit.ly/PeterAttiaMDTW Instagram: http://bit.ly/PeterAttiaMDIG Subscribe to The Drive: Apple Podcast: http://bit.ly/TheDriveApplePodcasts Overcast: http://bit.ly/TheDriveOvercast Spotify: http://bit.ly/TheDriveSpotify Google Play: http://bit.ly/TheDriveGooglePlay

🎤 SPEAKERS

• Dr. Tom Dayspring

  guest

  Lipidologist and clinical expert in lipid disorders and cardiovascular risk reduction therapies.

🧾 EPISODE SUMMARY

In this episode of Peter Attia MD, featuring Dr. Peter Attia and Dr. Tom Dayspring, #23–Tom Dayspring Part IV of V: statins, Zetia, PCSK9 inhibitors, niacin, cholesterol & the brain explores dayspring and Attia Dissect Lipid Drugs, Trials, Niacin Failures, and Statin-Brain Concerns Tom Dayspring and Peter Attia trace how lipid drugs developed, arguing that nearly all drugs that safely reduced events do so by enhancing LDL receptor-mediated clearance of ApoB particles, while the failed triparanol shows that blocking a different step in the pathway can be harmful.

🔗 RELATED EPISODES

409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles

#117 – Stanley Perlman, M.D., Ph.D.: Insights from a coronavirus expert on COVID-19

#150-Senator Bill Frist, MD: A modern Renaissance man's journey through science, politics & business

#130 - Carol Tavris, Ph.D. & Elliot Aronson, Ph.D.: Recognizing and overcoming cognitive dissonance

#96–David Epstein: How range of experience leads to better performance in a highly specialized world

#125 - John Arnold: The most prolific philanthropist you may not have heard of